How EOS Became A Leading Lip Balm Company

EOS is a leading beauty company that sells a variety of lip balm products as well as other health care and beauty care products. EOS which stands for Evolution Of Smooth is a high quality brand that has been on the market for just over seven years. The founders and CEO have never spoken about their business strategy until very recently. In a one-of-a-kind interview with Fast Company the co-founders of CEO shared how they became a multi-million dollar company.

Throughout the Fast Company article: https://www.fastcompany.com/3063333/startup-report/the-untold-story-of-how-lip-balm-upstart-eos-outdid-chapstick customers learn the history as well as the process and success of the EOS company. The EOS co-founder and CEO Sanjiv Mehra discusses his journey to create the product along with his two co-founders Jonathan Teller and Craig Dubitsky. All three spent time at some of the top startup companies in the world. Mehra once worked for top companies such as PepsiCo and Unilever. Adding all of their knowledge, tools, and experience together the three founders launched one of the most popular lip balm products on the market.

One of the main reasons why EOS(evolutionofsmooth.com) became as popular as it is, is due to the unique and colorful packaging design. When the co-founders first set out to create a product they wanted something that would stand out from the typical lip balm product. Not only are EOS products a very unique egg shape design but they also come in a variety of playful colors such as red, yellow and orange.

Another reason why EOS became as popular as it has is due to its large array of delicious flavors. Many standard lip balms only offer one or two basic flavors. EOS lip balms offer a large variety of flavors including mint, strawberry, raspberry, and even blueberry acai.

Although EOS already has a large array of great products to offer they are constantly working to add new and innovative products. Each product is designed to offer moisturizing and hydrating benefits. With so many great things to offer it is so easy to see why EOS has millions and millions of Facebook fans all over the world.

 

New Treatment for Multiple Sclerosis Found

New clinical trial results show that undergoing high-dose immunosuppressive therapy and then having the patient’s blood-forming stem cells transplanted brings on the reduction of relapsing-remitting multiple sclerosis (MS). MS is an autoimmune disease in which the central nervous system gets attacked by the immune system. The treatment is called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HTC). Five years after participants had received treatment; sixty-nine percent of them didn’t have any new brain lesions and did not experience symptoms of MS.

Studies have revealed that other methods of treatment have not been as successful as HDIT/HTC. The trial, named HALT-MS was funded by the National Institute of Allergy and Infectious Diseases (NIAID). NIAID-sponsored Immune Tolerance Network (ITN) conducted the study, of which the five-year results appeared in the American Academy of Neurology’s journal Neurology. NIAID director Anthony S. Fauci said that the extended findings suggest that a one-time treatment with HDIT/HTC may be better than any long-term medication given to people with any type of MS. The purpose of the experiment was to remove the disease-causing cells and keep the immune system in its normal state.

Dr. Shiva Gopal Vasishita is a practicing neurologist at Voorhees, New Jersey who works with the Kennedy National Hospital. He is among the 34 doctors in the hospital who specialize in neurology. Dr. Shiva Vasishita has an experience of over 38 years of experience in his area of expertise. He received his medical degree from Government Medical School Nagpur in 1979.

Dr. Gopal Vasishita is a member of the practice group known as Eastern Neurodiagnostic Associates and is also an expert in psychiatry. Dr. Gopal Vasishita accepts various insurance plans which include: Horizon Blue Cross Blue Shield, Aetna, and Medicare. He is a certified neurologist, licensed to practice in New Jersey (his license number is 25MA55133). His current place of practice is 2301 Evesham Road, Pavilion 800 Suite 2009, Voorhees, NJ.

JeanMarie Guenot Brings Promising Cancer Therapies To Light

 

A longtime accomplished specialist with significant expertise in the biotechnology and pharmaceutical industries, JeanMarie Guenot is at this time working to develop innovative autoimmune therapies for the treatment of cancer.  Newson6 covered her work in their piece “Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies” found here.

 

With her more than 20 years experience, as noted on her biography page at Guenot LLC, JeanMarie Guenot has worked with all phases of companies from research and development to corporate and business-related expansion as well as venture capital. She initially trained in physical and medicinal chemistry with a focus on protein structure prediction, X-ray and NMR refinement and drug design.

 

Prior to her current role as president and chief executive at San Francisco-based Amphivena Therapeutics, Guenot founded a start-up ophthalmic company, SKS Ocular, which focused on developing ocular drug delivery technologies and therapeutics for glaucoma and ocular inflammation.

 

She held a variety of positions that included business advisor for Hoffmann-La Roche in Shanghai, China and Basel, Switzerland; vice president of corporate and business development at PDL BioPharma and managing venture capital investments at Atlas Venture where she was also took part in building life science companies.

 

JeanMarie Guenot received her Ph.D. from the University of California, San Francisco and her MBA from The Wharton School at the University of Pennsylvania.

 

Making use of Jeanmarie Guenot’s education and building on her broad experience, Amphivena Therapeutics is working to eliminate blood cancers by cultivating therapies that adjust to a patient’s immune system.

 

Last year, Amphivena Therapeutics made it known that the US Food and Drug Administration (FDA) has acknowledged and accepted an investigational new drug application for AMV564, the company’s lead drug candidate.

 

Guenot commented in a statement that the acceptance of the first clinical trial of AMV564 symbolizes a crucial advancement effort for the company to produce a necessary therapeutic alternative for acute myeloid leukemia (AML) patients and their medical doctors.

 

She added Amphivena Therapeutics anticipates beginning its AMV564 clinical development program and weighing the impending possibilities for patients.  Read more about JeanMarie’s partnership with Takeda on their website.